HAWPF: AI 评分 49/100 — AI 分析 (4月 2026)

Haw Par Corporation Limited manufactures and markets healthcare products, primarily topical analgesics under the Tiger Balm and Kwan Loong brands. The company also has investments in securities and properties, with operations spanning across Asia and internationally.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Haw Par Corporation Limited is a Singapore-based healthcare company focused on manufacturing and distributing topical analgesics like Tiger Balm, alongside investments in securities and properties. With a strong presence in ASEAN and other Asian markets, the company boasts a high profit margin and significant dividend yield.

HAWPF是做什么的？

Haw Par Corporation Limited, established in 1969 and headquartered in Singapore, operates as a diversified company with core interests in healthcare, investments, and property. The company is renowned for its flagship healthcare segment, which manufactures and distributes topical analgesic products under the globally recognized Tiger Balm and Kwan Loong brands. These products are marketed across Singapore, ASEAN countries, other Asian countries, and internationally. Beyond healthcare, Haw Par's Investments segment actively invests in quoted securities, contributing to its overall financial performance. The company also owns and leases investment properties, comprising 45,324 square meters of commercial and industrial space located in Singapore and Malaysia. These properties generate rental income and contribute to the company's revenue stream. Additionally, Haw Par operates leisure-related businesses, including oceanariums, offering family and tourist-oriented attractions. The company also provides land, building, and office space leasing services, along with management support services, further diversifying its business operations. Haw Par's strategic diversification and established brand presence have solidified its position in the Asian market and beyond.

HAWPF的投资论点是什么？

Haw Par Corporation presents a compelling investment case based on its established healthcare brands, particularly Tiger Balm, which commands a loyal customer base across Asia. The company's high profit margin of 115.4% and a dividend yield of 9.41% suggest strong profitability and shareholder returns. While its low beta of 0.21 indicates lower volatility compared to the broader market, potential investors should carefully consider the risks associated with its OTC listing and reliance on a single product category. Growth catalysts include expanding its healthcare product line and leveraging its investment portfolio to generate additional revenue streams. The company's property holdings also provide a stable source of income.

HAWPF在哪个行业运营？

Haw Par Corporation operates within the global drug manufacturers industry, which is characterized by intense competition, stringent regulations, and evolving consumer preferences. The market for topical analgesics is driven by increasing demand for pain relief solutions, particularly among aging populations. Haw Par's established brands, such as Tiger Balm, provide a competitive advantage in this market. However, the company faces competition from both multinational pharmaceutical companies and regional players. The industry is also subject to regulatory scrutiny, requiring companies to adhere to strict quality control and safety standards.

Drug Manufacturers - General

Healthcare

HAWPF有哪些增长机遇？

Expanding product line within the healthcare segment: Haw Par can leverage its established brand reputation to introduce new healthcare products, such as supplements or related therapeutic products. The global market for dietary supplements is projected to reach $278 billion by 2024, presenting a significant growth opportunity for the company. Timeline: 2-3 years.
Geographic expansion into new markets: Haw Par can expand its presence beyond its current markets in Asia and explore opportunities in other regions, such as Europe and North America. The increasing demand for traditional medicine and natural remedies in these markets could drive growth. Timeline: 3-5 years.
Leveraging its investment portfolio for strategic acquisitions: Haw Par can utilize its investment portfolio to acquire complementary businesses or technologies in the healthcare sector. This could enable the company to diversify its product offerings and enhance its competitive position. Timeline: Ongoing.
Enhancing its e-commerce presence and digital marketing efforts: Haw Par can invest in its online sales channels and digital marketing initiatives to reach a wider customer base and drive sales growth. The increasing adoption of e-commerce platforms and digital marketing strategies presents a significant opportunity for the company. Timeline: 1-2 years.
Developing new formulations and delivery systems for its existing products: Haw Par can invest in research and development to create new formulations and delivery systems for its Tiger Balm and Kwan Loong products. This could enhance the efficacy and convenience of these products, attracting new customers and driving sales growth. Timeline: 2-4 years.

Market capitalization of $2.89 billion, reflecting its significant presence in the healthcare sector.
P/E ratio of 12.41, suggesting a potentially undervalued stock compared to its earnings.
High profit margin of 115.4%, indicating efficient operations and strong pricing power.
Gross margin of 56.0%, demonstrating the company's ability to control production costs.
Dividend yield of 9.41%, offering a substantial income stream for investors.

HAWPF提供哪些产品和服务？

Manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands.
Invests in quoted securities.
Owns and leases investment properties in Singapore and Malaysia.
Provides family and tourist-oriented leisure alternatives through oceanariums.
Leases land, building, and office space.
Offers management support services.

HAWPF如何赚钱？

Manufacturing and selling healthcare products, primarily topical analgesics.
Generating investment income from its portfolio of quoted securities.
Earning rental income from its investment properties.
Generating revenue from its leisure-related businesses.

Consumers seeking pain relief solutions.
Tenants of its investment properties.
Visitors to its oceanariums.
Businesses requiring land, building, and office space leasing services.

Strong brand recognition and reputation for its Tiger Balm and Kwan Loong products.
Established distribution network across Asia and internationally.
Diversified business model with interests in healthcare, investments, and property.
Experienced management team with a proven track record of success.

什么因素可能推动HAWPF股价上涨？

Ongoing: Expansion of Tiger Balm product line into new therapeutic areas.
Ongoing: Geographic expansion into emerging markets with growing demand for topical analgesics.
Upcoming: Potential acquisitions of complementary healthcare businesses to diversify revenue streams.
Ongoing: Continued investment in digital marketing and e-commerce to reach a wider customer base.
Upcoming: Development of new formulations and delivery systems for existing products to enhance efficacy and convenience.

HAWPF的主要风险是什么？

Potential: Increased competition from generic drug manufacturers.
Ongoing: Fluctuations in currency exchange rates impacting international sales.
Potential: Regulatory changes affecting the manufacturing and distribution of healthcare products.
Ongoing: Reliance on key brands (Tiger Balm) exposes the company to brand-specific risks.
Potential: Economic downturns affecting consumer spending on healthcare products.

HAWPF的核心优势是什么？

Strong brand recognition for Tiger Balm and Kwan Loong.
High profit margin and dividend yield.
Diversified business model.
Low beta, indicating lower volatility.

HAWPF的劣势是什么？

Reliance on a single product category (topical analgesics).
Limited geographic diversification.
OTC listing, which may reduce liquidity and investor confidence.
AI analysis pending, indicating potential gaps in investor information.

HAWPF有哪些机遇？

Expanding product line within the healthcare segment.
Geographic expansion into new markets.
Strategic acquisitions to diversify its business.
Enhancing its e-commerce presence and digital marketing efforts.

HAWPF面临哪些威胁？

Intense competition from multinational pharmaceutical companies.
Stringent regulations and quality control requirements.
Fluctuations in currency exchange rates.
Potential for product liability claims.

HAWPF的竞争对手是谁？

Alfred Mannich Pharma — Focuses on generic pharmaceuticals and OTC products. — (ALFRY)
Asahi Group Holdings, Ltd. — Diversified beverage and food company with pharmaceutical interests. — (APNHY)
Chiesi Farmaceutici S.p.A. — Specializes in respiratory and specialty care products. — (CHSYF)
Curaleaf Holdings Inc. — Focuses on cannabis-based health and wellness products. — (CURLF)
Daiichi Sankyo Company, Limited — Global pharmaceutical company with a broad range of products. — (DMPHF)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Ee Lim Wee
Headquarters: Singapore, SG
Founded: 1996

AI Insight

AI analysis pending for HAWPF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Haw Par Corporation Limited do?

Haw Par Corporation Limited is a diversified company primarily engaged in the manufacturing, marketing, and distribution of healthcare products, most notably the Tiger Balm and Kwan Loong brands of topical analgesics. These products are sold across Asia and internationally. In addition to its healthcare business, Haw Par also has investments in quoted securities and owns/leases investment properties in Singapore and Malaysia. The company further operates leisure businesses, including oceanariums, and provides management support services, showcasing a diversified revenue model centered around healthcare and strategic investments.

What do analysts say about HAWPF stock?

AI analysis is currently pending for HAWPF, therefore a summary of analyst consensus is unavailable. However, key valuation metrics include a P/E ratio of 12.41 and a dividend yield of 9.41%. Growth considerations should include the company's ability to expand its product line, penetrate new geographic markets, and leverage its investment portfolio. Investors should also consider the risks associated with its OTC listing and reliance on a single product category.

What are the main risks for HAWPF?

HAWPF faces several risks, including intense competition from both multinational pharmaceutical companies and generic drug manufacturers, which could erode its market share. Fluctuations in currency exchange rates can impact its international sales and profitability. Regulatory changes in the healthcare industry could increase compliance costs and affect its ability to market its products. The company's reliance on the Tiger Balm brand exposes it to brand-specific risks, such as negative publicity or changing consumer preferences. Economic downturns could also reduce consumer spending on healthcare products, impacting its revenue.